Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Roseanne Conner (née Harris) is played by Roseanne Barr. Roseanne, in a takeoff of her stand-up comedic and presumed real-life persona, is a bossy, loud, caustic, overweight, and dominant woman. She is also portrayed as smart, resourceful, and witty. She strives to control the lives of her sister, husband, children, co-workers, and friends. Despite a domineering nature, Roseanne is depicted as being a loving wife and mother who works hard and makes as much time for her husband and children as possible. She and her younger sister, Jackie, are the daughters of Beverly and Al Harris. Roseanne is married to Dan Conner and when the series begins they have three young children: Becky, Darlene, and David Jacob ("D.J."); a fourth child, Jerry Garcia, is born in the eighth season of the series. Roseanne and Dan mostly live paycheck-to-paycheck, raising a family amid the many hardships of poverty, obesity, and domestic troubles with love and humor. Roseanne works at the Wellman Plastics factory at the beginning of the show's run and quits after a conflict with her overbearing boss, Mr. Faber; she leads a walkout that includes Jackie and other co-workers. She is intermittently unemployed and holds jobs as a fast-food restaurant employee, a telemarketer, a bartender, and a shampooer/hair sweeper/receptionist at a beauty salon. Subsequently, she works for several years as a waitress in the luncheonette at Rodbell's department store located in the Lanford Mall (much to the chagrin of her daughters Becky and Darlene, who regularly hang out there).
Oxytocin+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Symbol Report: OXTR". HUGO Gene Nomenclature Committee. "Vasopressin and Oxytocin Receptors: OT". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Professors Mathematics or science: Arago, Berzelius, Biot, Curie, Frankenheim, Lehmann, Liebig, Mitscherlich, Ostwald, Pasteur, Reinitzer, Wöhler Mineralogy: Delafosse, Groth, Haüy, Neumann, Other employment: Brewster (editor), Romé de l'Isle (cataloguer), Sohncke (meteorological service), Wollaston (physician) Independently wealthy: Barlow, Herschel, Huygens In the nineteenth century there were informal schools of crystallography researchers in France (Arago, Biot, Curie, Delafosse, Haüy, Pasteur), Germany (Frankenheim, Groth, Lehmann, Liebig, Mitscherlich, Neumann, Reinitzer, Sohncke, Wöhler) and England (Barlow, Brewster, Herschel, Wollaston). Until the founding of Zeitschrift für Krystallographie und Mineralogie by Paul Groth in 1877 there was no lead journal for the publication of crystallographic papers. The majority of crystallographic research was published in the journals of national scientific societies, or in mineralogical journals. The inauguration of Groth's journal marked the emergence of crystallography as a mature science independent of geology.
=== 9 February === In its latest assessment, the Institute for the Study of War said that Russian forces had begun their next major offensive in the west of eastern Luhansk region, most of which is occupied by Russia. Dmitry Medvedev, member of Russia's security council, visited the Omsk Transport Engineering Plant (a tank factory) and made a statement, promising to "modernize thousands of tanks" and "increase production of modern tanks" in response to Ukraine receiving Western tanks. Volodymyr Zelenskyy, president of Ukraine, met with the European Council at Brussels and reported that his country intercepted plans by Russian secret services to "destroy" Moldova by a pro-Russian coup. This was also confirmed by Moldovan intelligence. The Ukrainian military claimed to have destroyed the first BMPT Terminator near Kreminna using artillery.
Sources: en.wikipedia.org
== Pharmacology == Similar to other benzodiazepines clotiazepam has anxiolytic, sedative, hypnotic, amnesic, anticonvulsant and muscle relaxant pharmacological properties. Clotiazepam binds to the benzodiazepine site of the GABAA receptor where it acts as a full agonist; this action results in an enhanced GABA inhibitory effect at the GABAA receptor which results in the pharmacological effects of clotiazepam. Clotiazepam has a short elimination half-life and is less prone to accumulation after repeated dosing compared to longer-acting benzodiazepine agents. It is metabolised via oxidation. Clotiazepam is metabolised to hydroxy-clotiazepam and desmethyl-clotiazepam. After oral ingestion of a single 5 mg dose of clotiazepam by three healthy volunteers the drug was rapidly absorbed. The elimination half-life of the drug and its metabolites range from 6.5 hours to 18 hours. Clotiazepam is 99 percent bound to plasma protein. In elderly men the elimination half-life is longer and in elderly women the volume of distribution is increased. Individuals with liver impairment have a reduced volume of distribution as well as a reduced total clearance of clotiazepam; renal impairment does not affect the kinetics of clotiazepam. The dose equivalent to 10 mg diazepam is thought to be between 5 and 10 mg clotiazepam.
The organ was then transplanted to live rabbits and functioned comparably to the native organ, suggesting potential as treatment for genital trauma. Oral mucosa tissue engineering uses a cells and scaffold approach to replicate the 3 dimensional structure and function of oral mucosa.
The caffeine content of instant coffee is generally less than that of brewed coffee. One study comparing various home-prepared samples came to the result that regular instant coffee (not decaffeinated) has a median caffeine content of 66 mg per cup (range 29–117 mg per cup), with a median cup size of 225 ml (range 170–285 mL) and a caffeine concentration of 328 μg/mL (range 102–559 μg/mL). In comparison, drip or filter coffee was estimated to have a median caffeine content of 112 mg, with a median concentration of 621 μg/mL for the same cup size. Regarding antioxidants, the polyphenol content of a 180 ml cup of instant coffee has been estimated to be approximately 320 mg, compared to approximately 400 mg in a cup of brewed coffee of the same size.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.